Exosens/€EXENS

05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX

About Exosens

Exosens is a high-tech company specializing in the innovation, development, manufacturing, and sale of advanced electro-optical technologies in amplification, detection, and imaging. Its product portfolio includes traveling wave tubes, advanced cameras, neutron and gamma detectors, instrument detectors, and light intensifier tubes, serving sectors such as defense, life sciences, industrial control, and nuclear energy. Founded over 85 years ago, the company rebranded from Photonis Group to Exosens in September 2023 to reflect its expanded technological scope. Headquartered in Mérignac, France, Exosens operates 12 production and R&D sites across Europe and North America, employing over 1,700 individuals. The company's strategic positioning is bolstered by sustained investments in innovation and a series of acquisitions, including Xenics, Proxivision, Telops, and Elmul since December 2022, enhancing its capabilities in detection and imaging technologies. (,)

Ticker

€EXENS

Primary listing

PAR

Industry

Aerospace & Defense
Headquarters

Employees

1,308

ISIN

FR001400Q9V2

Exosens Metrics

BasicAdvanced
€2B
62.95
€0.61
-
€0.10
0.26%

Bulls say / Bears say

Exosens' inclusion in the SBF 120 index enhances its visibility and liquidity, potentially attracting more institutional investors. (globenewswire.com)
The company's plan to build its first U.S. plant in Sturbridge, Massachusetts, positions it to capitalize on increased defense spending by NATO countries. (reuters.com)
Exosens reported a 35% increase in annual revenue to €394.1 million, surpassing guidance due to stronger-than-expected demand. (reuters.com)
Kepler Cheuvreux downgraded Exosens to 'reduce', citing limited sector growth potential and a share price exceeding justified valuations. (reuters.com)
The broker also revised its adjusted EPS forecasts downward, anticipating an increase in the effective tax rate to approximately 25% over the next two to three years as tax loss carry-forwards expire. (reuters.com)
Despite strong revenue growth, Exosens' shares have experienced volatility, with a 6.9% decline following the downgrade by Kepler Cheuvreux. (reuters.com)
Data summarised monthly by Lightyear AI. Last updated on 3 Jul 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.

Buy €EXENS

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs